Aurobindo Scolded Yet Again for Manufacturing Violations

Drug Industry Daily
A A
The FDA has cracked down once more on Indian pharma giant Aurobindo Pharma for manufacturing deficiencies at one of its facilities, slamming the company with yet another Form 483 over drugmaking violations and quality unit concerns.

To View This Article:

Login

Subscribe To Drug Industry Daily